Indlela i-Retrovirus noma i-RNA Virus esebenza ngayo

I-retrovirus igciwane lawo amagciwane afakwe kwi-RNA esikhundleni se-DNA. Njengamanye amagciwane, ama-retroviruses kudingeka asebenzise imishini yamaselula yezinto eziphilayo ezithinta ukwenza amakhophi ngokwabo. Nokho, ukutheleleka nge-retrovirus kudinga isinyathelo esengeziwe. I-genome ye-retrovirus idinga ukuguqulwa-ibhaliswe ku-DNA ngaphambi kokuthi ikopishwe ngendlela evamile.

I-enzyme eyenza lokhu kubhaliswa emuva kuyaziwa ngokuthi i-reverse transcriptase.

I-Retroviruses isebenzisa i-reverse transcriptase ukuze iguqule i-RNA eyodwa elinezintambo zibe i-DNA kabili elinezintambo. I-DNA egcina i-genome yamangqamuzana omuntu namaseli avela kwezinye izinhlobo zokuphila eziphakeme. Uma usuguqulwe kusuka ku-RNA kuya ku-DNA, i-DNA yegciwane ingahlanganiswa ne-genome yamaseli anegciwane. Lapho izinguqulo ze-DNA zegciwane lesandulela ngculaza zifakwe kwi-genome, iseli ke likhohliswa ekukopheni lezo zakhi zofuzo njengengxenye yenqubo evamile yokuphindaphinda. Ngamanye amazwi, iseli lenza umsebenzi wegciwane kuwo.

I-Retroviruses "i-retro" ngoba iphendulela ukuqondiswa kwenqubo evamile yokukopisha izakhi zofuzo. Ngokujwayelekile, amangqamuzana aguqula i-DNA ibe yi-RNA ukuze ingenziwa amaprotheni. Kodwa nge-retroviruses, inqubo kumele iqale ngokubuyela emuva. Okokuqala, i-RNA yegciwane iguqulwa ibe yi-DNA.

Khona-ke iseli lingakwazi ukukopisha i-DNA. Iseli lingaphinde libhalele i-DNA emuva kwe-RNA njengesinyathelo sokuqala sokwenza amaprotheni wegciwane.

Izibonelo

I-retrovirus eyaziwa kakhulu kunazo zonke ezithinta abantu i- HIV . Kodwa-ke, kunezinye izidakamizwa eziningana zabantu. Lezi zihlanganisa igciwane lesifo se-T-cell lymphotropic 1 (HTLV-1).

I-HTLV-1 ihlotshaniswa namanye ama-leukemas e-T-cell nama-lymphomas. Kunezinhlobo eziningi ze-retroviruses ezitholakale njengezifola ezinye izinhlobo.

Ukwelashwa kwe-HIV kungenye yezizathu abantu abajwayele ukujwayela umqondo wama-retrovirus. I-reverse transcriptase inhibitors yakha amanye amakilasi awaziwa yi-HIV . Ukuguqula i-transcriptase inhibitors kuvimbela i-HIV ukuthi ingahlanganiswa ne-genome yesitoreji. Lokhu, futhi, kugcina iseli lingenzi amakhophi wegciwane futhi linciphise ukuqhubekela phambili kokutheleleka. Kodwa-ke, kunezinkinga ezikhulayo ngokumelene nezidakamizwa eziningi kulezi zigaba.

I-retroviruses nayo isetshenziswa ngezinye izikhathi njengezindlela zokwethula izakhi zofuzo ngesikhathi sokuphathwa kwegciwane. Lokhu kungenxa yokuthi lezi zigciwane zombili zilula ukuguqula futhi zihlanganiswe kalula kwi-genome ye-host. Lokhu kusho ukuthi, ngombono, zingasetshenziswa ukudala imishini yamaselula ukwenza amaprotheni ngendlela eqhubekayo. Isibonelo, ososayensi basebenzise ama-retroviruses ukusiza amagundane ayisifo sikashukela abenza i-insulin yabo.

> Imithombo:

> Clevenbergh P, Cua E, Idamu E, Durant J, Schmit JC, Boulme R, Cottalorda J, Beyou A, Schapiro JM, Clavel F, Dellamonica P. Ukuqhathaniswa kwe-nonnucleoside reverse transcriptase inhibitor (NNRTI) ukuguquka okuhambisana nokumelene nokuphikisana Iziguli eziphethwe yi-NNRTI-naïve ezine-HIV. Izivivinyo ze-HIV Clinic. 2002 Jan-Feb; 3 (1): 36-44

> Elsner M, Terbish T, Jörns A, Naujok O, Wedekind D, Hedrich HJ, Lenzen S. Ukuguqulwa kwesifo sikashukela ngokusebenzisa ukwelashwa kwezakhi zofuzo zamashukela nge-hepatic insulin expression nge-lentiviral transduction. Mol Ther. 2012 Meyi; 20 (5): 918-26. i-doi: 10.1038 / umhlaka.

> Goldsmith CS. Ukwahlukana kwe-morphologic yegciwane elingaphezu kwezinga lomndeni. Ama-virus. 2014 Dec 9; 6 (12): 4902-13. i-doi: 10.3390 / v6124902.

> Peeters M, D'Arc M, uDelaporte E. Umsuka kanye nokuhlukahluka kwama-retrovirus abantu. I-AIDS Rev. 2014 Jan-Mar; 16 (1): 23-34.

> Sluis-Cremer N. Iphrofayili evelayo yokumelana nokuphikisana phakathi kwe-nonnucleoside HIV-1 reverse transcriptase inhibitors. Ama-virus. 2014 Jul 31; 6 (8): 2960-73. i-doi: 10.3390 / v6082960.

> I-Suerth JD, i-Labenski V, i-Schambach A. I-Alpharetroviral vectors: evela ku-agent edala umdlavuza ithuluzi eliwusizo lwe-gene therapy. Ama-virus. 2014 Dec 5; 6 (12): 4811-38. i-doi: 10.3390 / v6124811.